Dual Biologics May End Daily Pills Post-Kidney Transplant

Published Date: 02 Mar 2026

A novel dual biologic regimen combining dazodalibep and belatacept is well tolerated and could enable more than half the kidney transplant recipients to avoid broader metabolic pathway inhibitors.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot